Anti-CD19 CAR therapy for CLL
| Study . | N . | ORR . | CR . |
|---|---|---|---|
| University of Pennsylvania 2010*† | 3 | 3/3 | 2/3 |
| University of Pennsylvania 2014‡ | 24 | 10/24 | 5/24 |
| National Cancer Institute§ | 4 | 3/4 | 1/4 |
| National Cancer Institute|| | 4 | 4/4 | 3/4 |
| Memorial Sloan-Kettering¶ | 8 | 1 | 0 |
| Study . | N . | ORR . | CR . |
|---|---|---|---|
| University of Pennsylvania 2010*† | 3 | 3/3 | 2/3 |
| University of Pennsylvania 2014‡ | 24 | 10/24 | 5/24 |
| National Cancer Institute§ | 4 | 3/4 | 1/4 |
| National Cancer Institute|| | 4 | 4/4 | 3/4 |
| Memorial Sloan-Kettering¶ | 8 | 1 | 0 |
CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; CR, complete remission; ORR, overall response rate.
Please see Kalos et al.71
Please see Porter et al.70
Please see Porter et al.74
Please see Kochenderfer et al.67
Please see Kochenderfer et al.73
Please see Brentjens et al.68